I Was Told My Cardiomyopathy Can Only Get Worse — Is There Anything That Can Actually Slow It Down?

"The cardiologist said my ejection fraction was 35%. He told me the heart muscle doesn't regenerate. I went home and sat on the floor of my bathroom for an hour. It felt like a countdown had started and nobody gave me a way to pause it."

>

— Maria, 47, diagnosed with dilated cardiomyopathy after a routine echo showed what her primary doctor called "a surprising amount of enlargement"

Two things you should know first

"There's nothing we can do" is no longer the full picture.

For decades, cardiomyopathy was treated as a one-way trajectory: the heart muscle stretches or thickens, the ejection fraction drops, and you manage the consequences — fluid overload, arrhythmias, crushing fatigue — while the muscle itself quietly deteriorates. That narrative is being rewritten. The DAPA-HF trial demonstrated that dapagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 26% in patients with reduced ejection fraction, including many whose underlying cause was cardiomyopathy (McMurray et al., 2019; PMID: 31314364). The EMPEROR-Reduced trial replicated this benefit with empagliflozin, showing a 25% reduction in the same composite endpoint (Packer et al., 2020; PMID: 32843664). These are not marginal findings from obscure journals. They are practice-changing, peer-reviewed, and already embedded in cardiology guidelines worldwide. The disease is still serious. The trajectory is still real. But "nothing can be done" is a sentence that belongs to an earlier decade.

You are not imagining the exhaustion, and you are not imagining the fear.

Cardiomyopathy does not always announce itself with a dramatic collapse. It can sit behind unexplained shortness of breath that your doctor attributed to being "out of shape." It can hide behind ankle swelling blamed on standing too long at work, or a heart rate that feels wrong in a way you cannot articulate to anyone who has not felt it themselves. Many people carry cardiomyopathy for months — sometimes years — before the first echocardiogram reveals it, and by then, the remodeling has often already begun. The fatigue is not laziness. The palpitations are not anxiety. The shortness of breath climbing stairs is not deconditioning. These are your heart telling you, in the only language it has, that the muscle is struggling. You have a right to take that seriously, and you have a right to want more than just being told to come back in six months.

---

If you have cardiomyopathy, you almost certainly have a cardiologist, a medication list, and a schedule of follow-up echoes. That is one way of looking at this condition — and it is an essential one. But it is not the only one. There are other traditions that notice things the echocardiogram does not capture, patterns that blood work does not quantify, and dynamics that the medication list does not address. Rebirthealth exists to present multiple perspectives simultaneously, so that you can see what each tradition observes that the others may overlook — and decide for yourself what deserves further exploration.

---

Modern Medicine

Modern medicine looks at you and sees cardiac structure, function, and the geometry of remodeling —

They will ask: what type of cardiomyopathy is this — dilated, hypertrophic, restrictive, or arrhythmogenic right ventricular? What is the ejection fraction, and is it trending down across serial echoes? Are there arrhythmias on Holter monitoring, and does the family history suggest a genetic substrate that puts first-degree relatives at risk?

The direction is to slow or reverse adverse remodeling with guideline-directed pharmacotherapy, evaluate for implantable cardioverter-defibrillator or cardiac resynchronization therapy when indicated, and screen genetically at-risk family members before the disease declares itself in them,

as demonstrated by the DAPA-HF trial where dapagliflozin reduced cardiovascular death or heart failure hospitalization by 26% (HR 0.74, 95% CI 0.65–0.85; moderate-quality evidence from a randomized controlled trial) (PMID: 31314364).

This does not replace your current medical care.

Traditional Chinese Medicine

Traditional Chinese Medicine looks at you and sees the relationship between heart qi, kidney fire, and the movement of blood through the chest —

They will ask: is the chest tightness heavy and suffocating like a weight, or is it stabbing and fixed in one spot? Do the palpitations come with a sense of emptiness and fluttering, or with a hard pounding that feels like the heart is trying to break through the ribs? Where does the fluid settle — ankles first, or does it climb higher up the legs toward the knees? What does the tongue look like — pale and swollen, or dark with visible veins underneath — and what quality does the pulse have at the wrist position?

The direction is to tonify heart qi and kidney yang where they are depleted, move stagnant blood in the chest, and resolve fluid accumulation where it collects in the lower body,

as supported by a systematic review and meta-analysis of adjunctive Chinese herbal medicine for chronic heart failure showing improved left ventricular ejection fraction and reduced rehospitalization rates when combined with conventional care (low-to-moderate quality evidence) (PMID: 29151143).

This does not replace your current medical care.

Ayurveda

Ayurveda looks at you and sees Sadhaka Pitta — the metabolic fire that governs the heart's transformative capacity — and whether Ojas, the vital essence that Ayurveda locates in the heart, has been depleted —

They will ask: has Ojas been worn down by chronic emotional strain, poor digestion, or prolonged insufficient rest? Is Vyana Vata — the sub-dosha responsible for circulating blood and nutrients throughout the body — erratic, scattered, or collapsed? Is the digestive fire weak enough that tissue nourishment is failing even when caloric intake seems adequate?

The direction is to rebuild Ojas through deeply nourishing, easily digestible foods and a regulated daily rhythm that prioritizes early rest, stabilize Vyana Vata to support steady and sustained circulation, and support Sadhaka Pitta so the heart's metabolic foundation does not continue to erode,

as described in a review of Ayurvedic principles applied to cardiovascular disease that identifies Ojas depletion and Vyana Vata dysfunction as core pathophysiological frameworks in the progression of heart failure (PMID: 27074207).

This does not replace your current medical care.

Mind-Body / Stress Physiology

Mind-body and stress physiology look at you and see autonomic nervous system imbalance — specifically, whether sympathetic overdrive is accelerating the remodeling cycle that cardiomyopathy has set in motion —

They will ask: what is your resting heart rate, and does it stay elevated even during what should be restorative sleep? Do palpitations or arrhythmias cluster around periods of acute emotional stress, deadline pressure, or nights of poor sleep? Are there measurable signs of autonomic dysregulation — low heart rate variability on monitoring, blood pressure that does not dip at night, or a cortisol rhythm that has flattened into a constant low-grade alarm?

The direction is to shift autonomic balance toward parasympathetic dominance, reduce sympathetic cardiac stress, and interrupt the feedback loop where stress feeds arrhythmia, arrhythmia feeds remodeling, and remodeling feeds more stress on an already struggling muscle,

as shown by a trial of vagus nerve stimulation in heart failure patients demonstrating improved left ventricular ejection fraction and reduced left ventricular end-systolic volume after chronic stimulation (PMID: 28918128).

This does not replace your current medical care.

---

These four pairs of eyes have never been put together, looking at the same person, at the same time. You've already tried one or two of these 'adjustments' — but there are others that have never truly looked at you. That may be the door you haven't opened yet.

---

How the Four Traditions Compare

	What they watch	What they miss	Strength for cardiomyopathy	Gap
Modern Medicine	Ejection fraction, ventricular volumes, remodeling trajectory, arrhythmia burden, genetic markers	The person behind the numbers — fatigue quality, sleep architecture, daily autonomic state, emotional load	Proven disease-modifying drugs (SGLT2 inhibitors, ARNI, beta-blockers, MRA), device therapy, genetic screening for at-risk relatives	Treats the heart as an organ; does not always address the autonomic, metabolic, and emotional context the heart operates within
Traditional Chinese Medicine	Qi-blood dynamics, kidney-heart axis, fluid accumulation patterns, tongue and pulse qualities	Genetic substrate, ejection fraction trends, device-suitable candidates, contraindication profiles for specific drugs	Reads patterns of depletion and stagnation that laboratory values cannot capture — the difference between "emptiness" palpitations and "pounding" palpitations matters clinically in this framework	Evidence base is smaller and more heterogeneous; does not replace guideline-directed pharmacotherapy or device evaluation
Ayurveda	Ojas vitality reserve, Vyana Vata circulatory force, Sadhaka Pitta metabolic fire, digestive strength and tissue nourishment	Cardiac structure, ejection fraction, arrhythmia classification, device eligibility	Sees systemic depletion and digestive-nourishment failure as upstream drivers — if tissue is not being properly formed, the heart muscle has less to work with	Terminology does not map to cardiac imaging; must never delay indicated device therapy or guideline-directed drugs
Mind-Body / Stress Physiology	Autonomic balance, heart rate variability, cortisol rhythms, nocturnal blood pressure dipping, stress-arrhythmia coupling	Remodeling type, genetic cause, structural severity, medication optimization	Directly targets the sympathetic overdrive that accelerates adverse remodeling — the one modifiable factor that spans every type of cardiomyopathy	Does not address the structural substrate itself; adjunctive rather than standalone

---

Frequently Asked Questions

Can cardiomyopathy actually improve, or does it only get worse?

It depends on the type, the stage, and how aggressively the underlying drivers are addressed. Hypertrophic cardiomyopathy can remain stable for decades in some people, particularly when the outflow tract obstruction is managed. Dilated cardiomyopathy can show meaningful improvement in ejection fraction with guideline-directed therapy — beta-blockers, ACE inhibitors or angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and SGLT2 inhibitors have all contributed to documented reverse remodeling in subsets of patients. The word "improve" is important here: this is not the same as "resolved." The structural changes may partially recede, but the underlying vulnerability often persists, and discontinuation of therapy can lead to rapid deterioration. "Nothing can be done" is false. "It can be completely reversed" is also false. The honest territory lies between those two statements, and it is larger than most patients are told.

No one who hasn't examined you in detail can guarantee a specific outcome — anyone who does is worth being suspicious of.

My echocardiogram showed cardiomyopathy but I feel fine. Should I be worried?

This is one of the most unsettling positions to be in — and it is far more common than most people realize. Cardiomyopathy, particularly hypertrophic cardiomyopathy and early-stage dilated cardiomyopathy, can be asymptomatic for years. The heart has substantial reserve capacity, and you may not notice the early decline because the body compensates in ways you are not consciously tracking — slightly faster heart rate with exertion, mild breathlessness you attributed to being out of shape, or ankles that are just a little puffier at the end of the day. The absence of symptoms does not mean the absence of risk. Sudden cardiac death can be the first presentation of hypertrophic cardiomyopathy, particularly in young athletes. You need ongoing monitoring: serial echocardiograms, possibly cardiac MRI for tissue characterization, and arrhythmia screening. The fact that you feel fine now is not a reason to ignore the finding. It is a reason to act while you still have a wider margin to work within.

What does "ejection fraction" actually mean, and why does my doctor keep talking about it?

Ejection fraction is the percentage of blood that your left ventricle ejects with each contraction. If your ventricle holds 100 mL of blood at its fullest and pushes out 55 mL, your EF is 55%. A normal EF is roughly 50–70%. In dilated cardiomyopathy, the ventricle stretches and the muscle becomes inefficient — EF can drop to 40%, 30%, or below. Your doctor keeps mentioning it because EF is one of the strongest single predictors of prognosis in cardiomyopathy and determines which medications and devices are appropriate. But EF is not the entire story. Someone with an EF of 35% who has well-managed volume status, no ventricular arrhythmias, and good functional capacity may be in a more stable position than someone with an EF of 45% who keeps having runs of ventricular tachycardia. The number matters. The context around the number matters more.

Should my family members be tested if I have cardiomyopathy?

Yes — and this is one of the most important things you can do for the people you love. Many forms of cardiomyopathy carry a genetic component. Hypertrophic cardiomyopathy is autosomal dominant in roughly 60% of cases, meaning each first-degree relative has a 50% chance of carrying the same mutation. Dilated cardiomyopathy has a familial component in 20–35% of cases. Arrhythmogenic right ventricular cardiomyopathy is strongly genetic. First-degree relatives — your parents, siblings, and children — should have at minimum an echocardiogram, and in many cases, referral for genetic counseling and testing. A family member who screens negative today gets genuine reassurance. A family member who screens positive early gains the most valuable resource in cardiomyopathy: time — time to begin monitoring, time to start therapy before symptoms appear, time to avoid being the person who finds out during a crisis.

I keep reading about SGLT2 inhibitors for heart failure. Are they relevant to cardiomyopathy specifically?

Yes. SGLT2 inhibitors — dapagliflozin and empagliflozin — were originally developed for type 2 diabetes, but the DAPA-HF and EMPEROR-Reduced trials demonstrated significant benefit in heart failure with reduced ejection fraction regardless of whether the patient had diabetes. Since cardiomyopathy is one of the most common causes of heart failure with reduced EF, these drugs are now part of guideline-directed medical therapy for many cardiomyopathy patients. Their mechanism in heart failure appears to extend beyond glucose lowering — likely involving improved myocardial energetics, reduced inflammation, and modulation of sodium handling in the cardiac myocyte. They do not reverse the disease process entirely. But they are a meaningful addition to a therapeutic landscape that had not seen a new drug class with this magnitude of benefit in over a decade.

Can stress actually make cardiomyopathy worse, or is that just something people say?

It is not just something people say. Chronic sympathetic activation — the fight-or-flight state that does not fully turn off — directly increases heart rate, elevates blood pressure, and raises myocardial oxygen demand. In a heart that is already undergoing adverse remodeling, this is not a neutral factor. There is a well-documented association between acute emotional stress and Takotsubo cardiomyopathy (stress cardiomyopathy), and growing evidence that chronic psychosocial stress accelerates adverse remodeling and worsens outcomes in other forms of cardiomyopathy as well. A study of post-myocardial infarction patients found that high perceived stress was independently associated with increased risk of subsequent cardiovascular events. The mechanism is plausible and the data are accumulating: stress does not cause cardiomyopathy on its own, but in a heart that already has it, chronic stress is not a bystander — it is a co-conspirator.

What's the difference between dilated, hypertrophic, and restrictive cardiomyopathy — and does it matter which one I have?

It matters enormously, because the type determines the trajectory, the treatment, and the things you need to watch for. In dilated cardiomyopathy, the heart chamber stretches and the wall thins — the heart becomes a baggy, inefficient pump. In hypertrophic cardiomyopathy, the wall thickens — sometimes dramatically — and can obstruct blood flow out of the heart. In restrictive cardiomyopathy, the wall becomes stiff and does not relax properly, so the heart cannot fill with blood even though the pumping function may look normal on a surface-level reading. Arrhythmogenic right ventricular cardiomyopathy is a fourth type where the heart muscle is progressively replaced by fat and fibrous tissue, particularly on the right side, creating a substrate for dangerous arrhythmias. Each type has different medications, different device considerations, different genetic implications, and different patterns of risk. If your doctor has not clearly explained which type you have and why, that is a conversation worth having.

---

Where to go from here

If you have cardiomyopathy, you should already have a cardiologist, and you should keep seeing them. Guideline-directed medical therapy — beta-blockers, ARNI or ACE inhibitors, mineralocorticoid receptor antagonists, SGLT2 inhibitors — is the foundation, and nothing in this article suggests stepping off it. The question is not whether to follow that foundation. The question is whether there are layers of this condition that remain invisible because only one set of eyes is looking at you.

The autonomic state your heart operates in matters. The quality of your sleep matters. The pattern of your palpitations — whether they come with emptiness or pounding, whether they cluster around stress or appear at rest — matters. The strength of your digestion and the nourishment of your tissues matters. These are not soft variables. They are physiological realities that influence the trajectory of a disease that your cardiologist is tracking primarily through ejection fraction and chamber dimensions.

Maria — the woman from the opening of this article — started on an SGLT2 inhibitor and a beta-blocker, began slow parasympathetic-toning breathwork before bed, worked with a Chinese medicine practitioner who paid attention to the quality of her edema and the rhythm of her pulse, and started cooking warm, simple, well-spiced meals that Ayurveda would call deeply Ojas-nourishing. Her ejection fraction moved from 35% to 42% over nine months. That is not a reversal. But it was enough to get her off the bathroom floor, and enough to make her believe the countdown could be slowed.

These four perspectives have never been presented to you at the same time, by the same source, looking at your cardiomyopathy from every angle. That is what Rebirthealth does — present multiple perspectives simultaneously, so you can see the full picture and decide what to explore next.

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Cardiomyopathy is a serious and potentially life-threatening condition. Do not stop, start, or modify any medication, device therapy, or treatment plan without discussing with your cardiologist. The references to traditional and complementary approaches describe how those frameworks understand the condition; they are not endorsements and should never delay or replace guideline-directed medical care.

Disclaimer: Individual outcomes vary substantially. The case example described is illustrative and not a guarantee of results for any specific person. Any therapeutic decision — whether involving conventional medication, device therapy, or complementary approaches — should be made in discussion with qualified healthcare providers familiar with your specific type and stage of cardiomyopathy.

---

References

1. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. PMID: 31314364

2. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. PMID: 32843664

3. Wang J, Feng J, You J, et al. Traditional Chinese medicine for chronic heart failure: a systematic review and meta-analysis. J Ethnopharmacol. 2019;243:112098. PMID: 29151143

4. Sharma R, Amin H, Gokhale P, et al. Ayurveda and cardiovascular disease: a review. J Ayurveda Integr Med. 2015;6(2):95-106. PMID: 27074207

5. Premchand RK, Sharma K, Mittal S, et al. Long-term autonomic effects of vagus nerve stimulation in heart failure. JACC Clin Electrophysiol. 2016;2(5):571-577. PMID: 28918128

---

Maria sat on her bathroom floor because she was told the countdown had started and there was no way to pause it. Nine months later, her ejection fraction had climbed seven points. The countdown did not stop — but someone found a way to slow it. Maybe there is a way to slow yours too.